I would respond in two ways. There is more alignment across the drug review and approval system now than perhaps at any point in history. We do work very closely with pCPA, with PMPRB, with the provinces, with Health Canada and INESSS. I would say it's better than it's ever been.
I would also say that this new proposed supplemental process will begin to address many of the issues you've talked about, so having an opportunity for conditional listing, for example, having an opportunity to negotiate price and to conduct both the regulatory and the HTA assessment almost in parallel, has never been done in this country. We're moving in that direction, so I think you're going to start to see some of those things happen.